South San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, DiCE Molecules is raising $60,000,416.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Kevin Judice played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About DiCE Molecules
At DiCE Molecules, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DiCE to target protein-protein interactions with small molecules. In doing so, DiCE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program an orally bioavailable IL-17 antagonist for the treatment of psoriasis is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.

To learn more about DiCE Molecules, visit http://www.dicemolecules.com/

Contact:
Kevin Judice, Chief Executive Officer
650-566-1402
kevin@dicemolecules.com
https://www.linkedin.com/in/kevin-judice-ba18016/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved